FDA approves AstraZeneca treatment for cases reacting badly to vaccines

By Akshay Kedari  | Date: 2021-12-09

FDA approves AstraZeneca treatment for cases reacting badly to vaccines

The U.S. FDA has reportedly issued an emergency use authorization of synthetic AstraZeneca antibodies for the prevention of Covid-19 infections in people who have had a severe reaction to vaccines. This is the first time the U.S. health authority has granted emergency approval for such a purely preventative treatment.

According to the FDA, the drug Evusheld isn’t a replacement for vaccination in those for whom COVID-19 vaccination is advised and can only be used by patients with a weaker immune system or who are unable to be vaccinated due to medical reasons such as a severe allergic reaction. In such cases, the drug can be provided for people who are aged 12 or above.

For those unaware, Evusheld is a drug that combines two synthetic antibodies (tixagevimab and cilgavimab) and is administered as two consecutive intramuscular injections. These antibodies aid the immune system in combating the virus by attacking the virus's spike protein, which permits it to access and infect cells. 

As per a statement given by the FDA, it may be useful for pre-exposure protection for six months and cannot be given to someone who is already infected with the virus, though AstraZeneca is testing it for this purpose.

The drug is known to have possible side effects like allergic reactions, bleeding from the injection site, headaches, and lethargy.

The FDA's approval was based on a clinical trial that included unvaccinated adults over the age of 59, suffering from chronic diseases, or those who were at high risk of infection. The result showed that the therapy reduced the probability of developing COVID-19 by 77%.

In the United States, two antibody cocktails developed by Regeneron and Eli Lilly are presently approved for the prevention of infection, but only in those who have recently been exposed to the virus or who have a high risk of being exposed to the disease.

Source Credit:

https://www.ndtv.com/world-news/us-authorizes-astrazeneca-evusheld-drug-for-covid-treatment-in-some-cases-2643322

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More >>

More News By Akshay Kedari

Interfor Corporation acquires 100% equity interest in Chaleur Forest Products

Interfor Corporation acquires 100% equity interest in Chaleur Forest Products

By Akshay Kedari

Following this funding, Interfor's long-term debt will hold a weighted average interest of 5.30% Interfor registered a Net Debt to the Invested Capital ratio of nearly 10% as of October 31, 2022 Interfor Corporation, one of the world...

ESR's ARA and Export-Import Bank of China partner in a deal worth US$1B

ESR's ARA and Export-Import Bank of China partner in a deal worth US$1B

By Akshay Kedari

Leading real estate services and investment company, ESR Group Limited, has recently announced that its exclusively-owned subsidiary, ARA and the Export-Import Bank of China have inked a breakthrough collaboration in a deal worth USD 1 billion infras...

Circularise nabs $11M to bring circular economy to industrial supply chains

Circularise nabs $11M to bring circular economy to industrial supply chains

By Akshay Kedari

Leading software platform, Circularise recently announced that it has raised $11.3 million (€11 million) in funding as part of its Series A round in a bid to advance its mission to bring a circular economy to industrial supply chains. The fun...

Sebi approves Adani Group’s proposal for additional 26% stake in NDTV

Sebi approves Adani Group’s proposal for additional 26% stake in NDTV

By Akshay Kedari

Adani Group, an Indian conglomerate, recently opened an offer to acquire an additional 26% share in New Delhi Television (NDTV), which was positively accepted by the Indian market regulator Sebi. The deal, worth USD 60.78 million, is expected to b...

ADB and Indonesia team up on coal power plant retirement contract

ADB and Indonesia team up on coal power plant retirement contract

By Akshay Kedari

The Asian Development Bank and Indonesia, along with a private power company announced partnering to refinance and retire a coal-fired power plant under a groundbreaking carbon emissions reduction program. According to reliable sources, West Java&...